Gesynta Pharma
Phase 2Gesynta Pharma is a Swedish pharmaceutical company that develops unique drug candidates with the aim to reduce harmful inflammation and increase blood flow in the body’s microvasculature, thereby providing safe and efficacious treatments for several serious diseases.
Market Cap
Private
Pipeline
4
drug candidates
Patents
—
Publications
—
Private Company
Total funding raised: $30M
About
Gesynta Pharma is a Swedish pharmaceutical company that develops unique drug candidates with the aim to reduce harmful inflammation and increase blood flow in the body’s microvasculature, thereby providing safe and efficacious treatments for several serious diseases.
Small Molecules
Pipeline
44 drugs in pipeline
| Drug | Indication | Stage | Watch |
|---|---|---|---|
| GS-248 + Placebo | Systemic Sclerosis | Phase 2 | |
| Vipoglanstat + Placebo | Endometriosis | Phase 2 | |
| Formulation A GS-248 + Formulation B GS-248 | Pharmacokinetic | Phase 1 | |
| GS-248 + Placebo | Healthy | Phase 1 |
Funding History
2Total raised:$30M
Series A$22MOct 15, 2022
Seed$8MFeb 15, 2020